Affordable Access

Development of inactivated vaccine against virus causing haemorrhagic fever with renal syndrome.

Authors
  • Yamanishi, K
  • Tanishita, O
  • Tamura, M
  • Asada, H
  • Kondo, K
  • Takagi, M
  • Yoshida, I
  • Konobe, T
  • Fukai, K
Type
Published Article
Journal
Vaccine
Publisher
Elsevier
Publication Date
Jun 01, 1988
Volume
6
Issue
3
Pages
278–282
Identifiers
PMID: 3138829
Source
Medline
License
Unknown

Abstract

B-1 virus belonging to the hantavirus group was serially passaged in the brains of newborn mice. Inactivated vaccine was prepared from the brains after inactivation with formalin and then purification by ultracentrifugation. The antigenic potency of this vaccine in vitro was determined by antibody-bound enzyme-linked immunosorbent assay (ELISA) and serial diluted vaccine bound to an aluminium hydroxide gel was inoculated into Balb/c mice to test immunogenicity. After two injections of this vaccine preparation, antibodies were detected in the mice by immunofluorescent, neutralizing and haemagglutination inhibition antibody tests. When mice immunized with this vaccine were challenged with B-1 virus and Hantaan virus (KHF-83-61BL strain), the virus titres in their lungs and spleens were significantly less than those in non-immunized mice. These results suggest that inactivated B-1 virus vaccine is effective against virus challenge by homotypic (B-1 virus) and heterotypic (Hantaan virus) viruses.

Report this publication

Statistics

Seen <100 times